Your browser doesn't support javascript.
loading
Impact of the COVID-19 epidemic on mortality in rural coastal Kenya
Mark Otiende Mr.; Amek Nyaguara; Christian Bottomley; David Walumbe; George Mochamah; David Amadi; Christopher Nyundo; Eunice Kagucia; Anthony Etyang'; Ifedayo Adetifa; Eric Maitha; Elwyn Chondo; Eddy Nzomo; Rashid Aman; Mercy Mwangangi; Patrick Amoth; Kadondi Kasera; Wangari Ng'ang'a; Edwine Barasa; Benjamin Tsofa; Joseph Mwangangi; Philip Bejon; Ambrose Agweyu; Tom Williams; Anthony Scott.
Affiliation
  • Mark Otiende Mr.; KEMRI-Wellcome Trust Research Programme
  • Amek Nyaguara; KEMRI-Wellcome Research Trust Programme, Kilifi, Kenya
  • Christian Bottomley; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
  • David Walumbe; KEMRI-Wellcome Research Trust Programme, Kilifi, Kenya
  • George Mochamah; KEMRI-Wellcome Research Trust Programme, Kilifi, Kenya
  • David Amadi; KEMRI-Wellcome Research Trust Programme, Kilifi, Kenya
  • Christopher Nyundo; KEMRI-Wellcome Research Trust Programme, Kilifi, Kenya
  • Eunice Kagucia; KEMRI-Wellcome Research Trust Programme, Kilifi, Kenya
  • Anthony Etyang'; KEMRI-Wellcome Research Trust Programme, Kilifi, Kenya
  • Ifedayo Adetifa; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
  • Eric Maitha; Department of Health, Kilifi County, Kenya
  • Elwyn Chondo; Department of Health, Kilifi County, Kenya
  • Eddy Nzomo; Kilifi County Hospital, Kilifi, Kenya
  • Rashid Aman; Ministry of Health, Government of Kenya, Nairobi, Kenya
  • Mercy Mwangangi; Ministry of Health, Government of Kenya, Nairobi, Kenya
  • Patrick Amoth; Ministry of Health, Government of Kenya, Nairobi, Kenya
  • Kadondi Kasera; Ministry of Health, Government of Kenya, Nairobi, Kenya
  • Wangari Ng'ang'a; Presidential Policy and Strategy Unit, The Presidency, Government of Kenya, Nairobi, Kenya
  • Edwine Barasa; KEMRI-Wellcome Research Trust Programme, Kilifi, Kenya
  • Benjamin Tsofa; KEMRI-Wellcome Research Trust Programme, Kilifi, Kenya
  • Joseph Mwangangi; KEMRI-Wellcome Research Trust Programme, Kilifi, Kenya
  • Philip Bejon; KEMRI-Wellcome Research Trust Programme, Kilifi, Kenya
  • Ambrose Agweyu; KEMRI-Wellcome Research Trust Programme, Kilifi, Kenya
  • Tom Williams; KEMRI-Wellcome Research Trust Programme, Kilifi, Kenya
  • Anthony Scott; KEMRI-Wellcome Research Trust Programme, Kilifi, Kenya
Preprint in English | medRxiv | ID: ppmedrxiv-22273516
ABSTRACT
BackgroundThe impact of COVID-19 on all-cause mortality in sub-Saharan Africa remains unknown. MethodsWe monitored mortality among 306,000 residents of Kilifi Health and Demographic Surveillance System, Kenya, through four COVID-19 waves from April 2020-September 2021. We calculated expected deaths using negative binomial regression fitted to baseline mortality data (2010-2019) and calculated excess mortality as observed-minus-expected deaths. We excluded deaths in infancy because of under-ascertainment of births during lockdown. In February 2021, after two waves of wild-type COVID-19, adult seroprevalence of anti-SARS-CoV-2 was 25.1%. We predicted COVID-19-attributable deaths as the product of age-specific seroprevalence, population size and global infection fatality ratios (IFR). We examined changes in cause of death by Verbal Autopsy (VA). ResultsBetween April 2020 and February 2021, we observed 1,000 deaths against 1,012 expected deaths (excess mortality -1.2%, 95% PI -6.6%, 5.8%). Based on SARS-CoV-2 seroprevalence, we predicted 306 COVID-19-attributable deaths (a predicted excess mortality of 30.6%) within this period. Monthly mortality analyses showed a significant excess among adults aged [≥]45 years in only two months, July-August 2021, coinciding with the fourth (Delta) wave of COVID-19. By September 2021, overall excess mortality was 3.2% (95% PI -0.6%, 8.1%) and cumulative excess mortality risk was 18.7/100,000. By VA, there was a transient reduction in deaths attributable to acute respiratory infections in 2020. ConclusionsNormal mortality rates during extensive transmission of wild-type SARS-CoV-2 through February 2021 suggests that the IFR for this variant is lower in Kenya than elsewhere. We found excess mortality associated with the Delta variant but the cumulative excess mortality risk remains low in coastal Kenya compared to global estimates.
License
cc_by
Full text: Available Collection: Preprints Database: medRxiv Type of study: Experimental_studies / Observational study / Prognostic study Language: English Year: 2022 Document type: Preprint
Full text: Available Collection: Preprints Database: medRxiv Type of study: Experimental_studies / Observational study / Prognostic study Language: English Year: 2022 Document type: Preprint
...